Approval · Notice of Compliance 18034 · 2016
EPIVAL: Notice of Compliance 18034
Issued April 22, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18034
- Date
- April 22, 2016
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add "anjan drug private limited" as a new starting material and drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EPIVAL | Not yet assigned | — |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB